The scale of generic uptake in the major markets

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Elen11)
(Image: Getty/Elen11)

Related tags IGBA Generics Mutual recognition Harmonization

The divergence across global market penetration of generic medicines is broad, with some countries’ markets worth close to half of the entire sector or as low as one fifth, according to IGBA.

The International Generics Pharmaceutical Alliance (IGBA), an international network of generic medicines associations, released a report​ that maps the varying levels of uptake of generics medicine, and the resulting value of its share across the entire pharmaceutical market.

As can be seen in the map below, the US actually has the greatest generics penetration by volume, at 90%, but this accounts for only 22% of the overall value of the market – one of the lowest levels across the countries studied.

At the opposite end of the spectrum is South Africa, which has one of the lowest levels of volume, 69.6%, but the overall value of the generics market is close to half, at 47.5%.

Image
Source: International Generics Pharmaceutical Alliance

Improving generic entry

To encourage the further entry of generics onto the global market, IGBA released an additional report​, which looked at how the global regulatory system could facilitate this through a harmonized approach.

The report notes that many countries have developed their own regulatory good manufacturing practice (GMP) standards, which necessitates multiple countries carrying out inspections at the same company – often duplicating results.

IGBA noted that such repeated inspections are of ‘significant concern’ for the manufacturers of active pharmaceutical ingredients (APIs) and finished products. This is due to the high costs for the companies and occasionally diverging regulatory opinion.

As a result, the organization is calling for greater global harmonization through the development of mutual recognition agreements, such as that recently agreed​ between the US Food and Drug Administration and the European Medicines Agency.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines